CureVac (NASDAQ:CVAC) Trading Up 7.7% – Here’s Why

by · The Cerbat Gem

CureVac (NASDAQ:CVAC – Get Free Report)’s share price traded up 7.7% on Monday . The stock traded as high as $3.59 and last traded at $3.48. 269,297 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 797,755 shares. The stock had previously closed at $3.23.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $16.00 target price on shares of CureVac in a report on Friday, February 14th.

Check Out Our Latest Analysis on CureVac

CureVac Trading Up 5.7 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The business’s fifty day simple moving average is $3.04 and its 200 day simple moving average is $3.18. The stock has a market cap of $766.11 million, a price-to-earnings ratio of 6.21 and a beta of 2.48.

CureVac (NASDAQ:CVAC – Get Free Report) last posted its quarterly earnings results on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The business had revenue of $15.44 million during the quarter, compared to analyst estimates of $6.40 million. On average, research analysts predict that CureVac will post 0.72 EPS for the current year.

Hedge Funds Weigh In On CureVac

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its position in CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock worth $162,000 after buying an additional 4,425 shares during the period. Signaturefd LLC lifted its position in CureVac by 29.2% in the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company’s stock valued at $123,000 after purchasing an additional 8,170 shares during the last quarter. XTX Topco Ltd lifted its position in CureVac by 90.2% in the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company’s stock valued at $83,000 after purchasing an additional 11,553 shares during the last quarter. Barclays PLC boosted its stake in CureVac by 51.8% during the 4th quarter. Barclays PLC now owns 34,836 shares of the company’s stock valued at $118,000 after purchasing an additional 11,890 shares during the period. Finally, Two Sigma Advisers LP acquired a new stake in shares of CureVac in the fourth quarter valued at approximately $48,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Company Profile

(Get Free Report)

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

Featured Stories